Abstract RF6-02: DESTINY-Breast11 (DB-11) safety: neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: University of Milan, European Institute of Oncology, LMU Klinikum, Ludwig-Maximilians-Universität München, Jewish General Hospital, McGill University, Memorial Sloan Kettering Cancer Center, Fudan University Shanghai Cancer Center, Sagara Hospital, Cancer Trials Ireland, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Vall d'Hebron Institute of Oncology, National Center for Global Health and Medicine, CHU de Québec-Université Laval, Regional Cancer Center, Thiruvananthapuram, Chang Gung Memorial Hospital, Taoyuan Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital, Cardinal Santos Medical Center, Grupo Hospitalar Conceição, AstraZeneca (United States), AstraZeneca (United Kingdom), Yale Cancer Center, Yale University
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129486052